Thorp M, Pulliam J
St. Vincent's Medical Center, Portland, OR 97225, USA.
Am J Nephrol. 1998;18(5):448-51. doi: 10.1159/000013369.
The use of recombinant human erythropoietin (rHuEPO) has been extensively studied among patients with anemia of chronic renal failure. Less well described is its safe use during pregnancy. We report a case of a 17-year-old gravid renal transplant patient with underlying renal insufficiency who became severely anemic and responded to rHuEPO. As the number of renal transplant recipients who become pregnant increases, the need for correction of anemia of chronic renal failure during pregnancy may rise as well. Our case illustrates the use of rHuEPO in this situation.
重组人促红细胞生成素（rHuEPO）在慢性肾衰竭贫血患者中的应用已得到广泛研究。而其在孕期的安全使用情况则描述较少。我们报告一例17岁的妊娠肾移植患者，该患者存在潜在肾功能不全，出现严重贫血并对rHuEPO有反应。随着妊娠的肾移植受者数量增加，孕期纠正慢性肾衰竭贫血的需求可能也会上升。我们的病例说明了rHuEPO在这种情况下的应用。
